Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Miguel Bronchud: A New Molecular Switch in Prostate Cancer Treatment Resistance
1+ hour, 32+ min ago (480+ words) “Prostate cancers – ‘maybe lost in translation’? New hopes for more effective treatments ‘This is the first time anyone’s ever shown that the identity of the cell can be regulated by inhibiting translation’ said at the Fred Hutch Institute in Seattle…...
Kimryn Rathmell: Welcoming Dr. Liza Makowski to OSU Comprehensive Cancer Center - OncoDaily
18+ hour, 3+ min ago (366+ words) Kimryn Rathmell, Chief Executive Officer of Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, shared on LinkedIn: “I’m thrilled to welcome the newest member of our OSU Comprehensive Cancer Center, Dr. Liza Makowski. Breakthroughs in…...
St. George hospital expands services for cancer, seeks to reduce helicopter response times
22+ hour, 32+ min ago (441+ words) ST. GEORGE — Intermountain Health celebrated two expansions at the St. George Regional Hospital this week — one to its flight and ambulance services and anther to its cancer center. A new emergency base will improve coordination and response times, while the…...
Metabolic Weaknesses Exposed in Prostate Cancer That Resists Enzalutamide
1+ day, 3+ hour ago (630+ words) Enzalutamide transformed the treatment of advanced prostate cancer when it entered clinical practice, offering men with castration-resistant disease a potent way to block the androgen receptor signaling that drives tumor growth. Yet resistance to the drug emerges with dispiriting regularity,…...
Metastatic Hormone Refractory Prostate Cancer Clinical Trial Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
2+ day, 16+ hour ago (71+ words) Metastatic Hormone Refractory Prostate Cancer Clinical Trial openPR.com Metastatic Hormone Refractory Prostate Cancer Clinical Trial Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Press release from: ABNewswire Permanent link to this press release:…...
Integrating a Nurse-Led Exercise Intervention Into Lymphoma Care
2+ day, 19+ hour ago (356+ words) A recent study was carried out to explore whether implementing a structured, nurse-led exercise program could help alleviate the negative chemotherapy effects that patients with lymphoma can experience during treatment, such as “psychological distress, sleep disturbance, and cognitive decline.” A…...
Ruben Mesa։ Antoinette Tan Named Inaugural Chair of the Department of Cancer Medicine at Wake Forest University School of Medicine - OncoDaily
2+ day, 22+ hour ago (119+ words) Ruben Mesa։ Antoinette Tan Named Inaugural Chair of the Department of Cancer Medicine at Wake Forest University School of Medicine oncodaily.com Ruben Mesa։ Antoinette Tan Named Inaugural Chair of the Department of Cancer Medicine at Wake Forest University School…...
Erin Clifford to Speak at CBA on Holistic Wellness
3+ day, 3+ hour ago (169+ words) Clifford Law Offices Recognized leaders in personal injury and wrongful death case litigation in medical malpractice, train accidents, construction, transportation, aviation litigation, and other complex matters. Erin Clifford to Speak at CBA on Holistic Wellness Clifford, who holds a J.D. from…...
Combination Therapy May Improve Immune Response Against Advanced Prostate Cancer
3+ day, 4+ hour ago (409+ words) Northwestern University Combination Therapy May Improve Immune Response Against Advanced Prostate Cancer Combining the targeted therapy olaparib with a supplemental immunotherapy may improve immune response in a subgroup of patients with metastatic castration-resistant prostate cancer who responded poorly to initial…...
XFOR: Phase III enrollment nears completion, with launch targeted for late 2028 or early 2029
3+ day, 3+ hour ago (75+ words) TradingView Mavorixafor's phase III trial for chronic neutropenia is on track with a reduced enrollment target and strong FDA alignment. Operational changes have improved enrollment, and a new study will address G-CSF reduction. Commercial launch is targeted for late 2028 or…...